Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment
Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who are being treated with radium-223 (Xofigo) plus enzalutamide... Read More
Tackle Racial Inequalities in Cancer Care
Cultural competence, multidisciplinary efforts with diverse faculty, and high-risk screening programs could help to address critical gaps and cancer disparities.... Read More
APPs Are Key in GU Cancer Care
Advanced practice providers are essential in treating patients with genitourinary cancers, especially as there is a shortage of clinicians in... Read More
Deciding Which Patients May Benefit from Adding Frontline Chemo to ADT for Metastatic Prostate Cancer
Recent trials have determined a survival benefit when chemotherapy is added to frontline treatment for patients with hormone-sensitive metastatic prostate... Read More